| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
A recombinant protein containing part of the dengue (DEN) 2 envelope protein was evaluated as a subunit immunogen for vaccination against DEN virus infection. A gene fragment encoding amino acids 298-400 (B domain) of the DEN-2 virus envelope was expressed as a fusion protein with the maltose binding protein (MBP) of Escherichia coli. This recombinant, DEN-2(B)/MBP, was purified and analyzed for its antigenicity, immunogenicity, and ability to protect mice against lethal challenge. The recombinant antigen reacted with a DEN-2 type-specific neutralizing monoclonal antibody (3H5), DEN-2 hyperimmune mouse ascitic fluid, and DEN-2 immune human sera. When administered to mice, DEN-2(B)/MBP elicited a DEN-2 virus neutralizing antibody response that conferred partial protection against challenge infection with a lethal dose of DEN-2 virus administered by intracranial inoculation. In addition, no replication of DEN-2 virus was detectable in the brains of the immunized mice as compared with control mice that were killed six days after challenge. Sera from immunized mice revealed no cross-neutralizing antibody to any of the other DEN serotypes in the plaque-reduction neutralization test. These findings warrant further studies with the DEN-2(B)/MBP antigen as a potential human vaccine candidate. An effective vaccine could prevent thousands of cases of illness and many deaths each year resulting from DEN virus infections.
This article has been cited by other articles:
|
|
 |
|
  B. Etemad, G. Batra, R. Raut, S. Dahiya, S. Khanam, S. Swaminathan, and N. Khanna An Envelope Domain III-based Chimeric Antigen Produced in Pichia pastoris Elicits Neutralizing Antibodies Against All Four Dengue Virus Serotypes Am J Trop Med Hyg, September 1, 2008; 79(3): 353 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fernandez, D. R. Palmer, M. Simmons, P. Sun, J. Bisbing, S. McClain, S. Mani, T. Burgess, V. Gunther, and W. Sun Potential Role for Toll-Like Receptor 4 in Mediating Escherichia coli Maltose-Binding Protein Activation of Dendritic Cells Infect. Immun., March 1, 2007; 75(3): 1359 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Simmons, K. R. Porter, C. G. Hayes, D. W. Vaughn, and R. Putnak Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques J. Virol., October 1, 2006; 80(19): 9577 - 9585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. KHANAM, B. ETEMAD, N. KHANNA, and S. SWAMINATHAN INDUCTION OF NEUTRALIZING ANTIBODIES SPECIFIC TO DENGUE VIRUS SEROTYPES 2 AND 4 BY A BIVALENT ANTIGEN COMPOSED OF LINKED ENVELOPE DOMAINS III OF THESE TWO SEROTYPES Am J Trop Med Hyg, February 1, 2006; 74(2): 266 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Roehrig, K. E. Volpe, J. Squires, A. R. Hunt, B. S. Davis, and G.-J. J. Chang Contribution of Disulfide Bridging to Epitope Expression of the Dengue Type 2 Virus Envelope Glycoprotein J. Virol., March 1, 2004; 78(5): 2648 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Chambers, Y. Liang, D. A. Droll, J. J. Schlesinger, A. D. Davidson, P. J. Wright, and X. Jiang Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model J. Virol., March 15, 2003; 77(6): 3655 - 3668. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
